Objectives: The aim of the study was to evaluate whether expert review of outside cervical cytology affects patient care.
C ervical cancer is the 21st most common cancer among women in the United States with an estimated 12,820 new cases to be diagnosed in 2017. 1 It accounts for 0.7% of all cancer-related deaths in the United States. 1 In the developed world, this cancer is increasingly rare because of improved access to medical care and effective screening programs. According to the Centers for Disease Control and Prevention, roughly 19 million Pap tests are performed annually. 2 The Bethesda reporting system, established in 1988, has been the standard for reporting cervical cytology. Since 1988, this reporting system has been modified several times, with the most recent update being in 2014. 3 An estimated 2.3 million women will have Pap tests identified as atypical cells of uncertain significance (ASC-US), 1.3 million are identified as low-grade squamous intraepithelial lesions (LSIL) and 550,000 will be reported as high-grade squamous intraepithelial lesions (HSIL). 4 This in turn leads to many colposcopies, biopsies, and excisional procedures.
At our National Cancer Institute-designated Comprehensive Cancer Center in Upstate New York, more than 400 new patients were referred for a second opinion for abnormal cervical cytology since 2004. These patients were initially screened by community gynecologists, family physicians, and midlevel providers. The original abnormal cytology results triggering the referral were obtained at community hospitals and clinics. As part of the routine new patient workup, all cytology slides are reviewed by an expert gynecologic cytopathologist and an interpretation is given.
Interobserver differences in cervical cytology interpretations are well described, with as many as 57% ASC-US Pap tests downgraded upon review. 5 There is also significant discordance observed with HSIL cytology, with as much as 27% reinterpreted as LSIL and 23% as ASC-US. 5 An additional study in Cancer Cytopathology showed interobserver differences with ASC-US Pap tests, which were interpreted as negative, ASC-US, or LSIL 86% of the time, and ASC-H Pap tests, being interpreted as negative, HSIL, and ASC-H 69.7% of the time. 6 We sought to review all new patient visits for abnormal cervical cytology at our institution and compare the initial cytology report with our expert review to see whether this impacts patient care with regard to newly discovered high-grade lesions and cancer diagnosis. We hypothesized that any differences between outside cytology reports and the expert review would not significantly alter patient care.
MATERIALS AND METHODS
This study is a retrospective chart review consisting of all new patients seen at our institution between January 1, 2004, and December 31, 2016, for the diagnosis of cervical dysplasia. To be included in the study, outside cervical cytology reports and the expert review performed by our institution needed to be available. The outside cytology review was compared with the expert review, and if the reports were not congruent, then additional information was collected, including any further treatments. See Figure 1 for categorization of cytology. This protocol was approved by the Roswell Park Cancer Institute Institutional Review Board.
Role of the Funding Source
This work was supported through the NIH Grant T32CA108456, which provided the funding to have the medical records queried to create the study list.
RESULTS
Four hundred twenty-four new patient visits for cervical cytology were identified and 246 met inclusion criteria. See Figure 2 for patient eligibility. Most charts excluded were for incorrect coding. For example, the patient was not actually referred for cervical dysplasia, outside records were incomplete, or the expert review was not performed.
Most cytology reports (165/246, 67.1%) were congruent between the outside report and the expert review. Eighty one (32.9%) of the reports were discordant, and of these, 50.6% 1 (41/81) led to a new diagnosis. See Figure 3 for distribution of reports. Twenty-four patients had cytology changed from low grade to high grade, 17 (71%) underwent an excisional procedure, and 1 (4.2%) had a laser ablative procedure. Cervical intraepithelial neoplasia (CIN) 2 or 3 was found in 11 (64.7%) of excisional procedure specimens. Cervical intraepithelial neoplasia 1 was found in 4 (23.5%) of excisional procedure specimens, and no dysplasia was found in 2 (11.8%).
In the high grade downgraded to low-grade group, 1 excisional procedure was performed with CIN 3 found on the specimen. One patient who had an ASC-H read outside Pap smear and was read as cancer on expert review was diagnosed with a stage 1A1 adenocarcinoma of the cervix after excisional procedure and went on to have a laparoscopic hysterectomy.
In the atypical glandular cells to cancer group, the first patient was diagnosed with a stage 1A1 squamous cell carcinoma of the cervix after excisional procedure and then underwent minimally invasive hysterectomy. The second atypical glandular cells to cancer patient underwent an excisional procedure, was diagnosed with a stage 1B2 serous adenocarcinoma of the cervix, and was treated with chemoradiation.
DISCUSSION
This study highlights the known interobserver differences when evaluating cervical cytology. Although previous studies 5, 6 have demonstrated interobserver differences in interpreting cytology results, there is a paucity of reports comparing community practice results with academic review since the widespread introduction of human papillomavirus (HPV) co-testing in clinical practice. The purpose of this article was to evaluate whether the routine practice of expert review of community cytology reports impacted patient care. Six patients identified as having negative cytology on expert review avoided colposcopy and biopsies altogether. One patient who had high-grade cytology downgraded to low-grade cytology and the excisional procedure pathology showed CIN 3 highlighted that expert review was not useful in this situation. Also included in this study is 1 patient who self-referred for a second opinion and had a history of cervical dysplasia, but most recent Pap test was normal so the reason for expert review in her case is not clear. The total cost of second cytologic review amounted to an estimated US $84,000 for the entire study group. One could imagine that if the practice of expert review was eliminated, this could potentially lead to more unnecessary colposcopies, biopsies, and potentially excisional procedures, especially in the low-grade cytology category of patients as we identified negative cytology in this group but our numbers were small. A specific limitation of this study is that 179 patient records were excluded, which may have impacted our findings as well as the high-risk HPV report not being in many outside records; therefore, this information was not included in our findings.
In most cases, when a patient has an ASC-US HPV-positive, LSIL, or HSIL Pap test, the American Society for Colposcopy and Cervical Pathology guidelines are followed, and this is immediately followed up with colposcopy and cervical biopsies. The patients with a low-grade Pap test that is upgraded to high grade would have had a colposcopy and biopsy regardless so the change in pathology was not clinically significant in this situation.
One way to eliminate the interobserver difference seen with cytology would be to use primary HPV testing. In 2015, the Society of Gynecologic Oncology endorsed primary HPV testing for cervical cancer screening in women aged 25 years or older as an alternative to traditional cytology with HPV testing. 7 One clear advantage of primary high-risk HPV testing is that a negative high-risk HPV test provides greater reassurance that CIN 3 or greater is absent compared with a negative cytology alone. 7 Patients testing positive for HPV 16 and 18 are recommended to have a colposcopy with possible biopsies. Although accepted as an alternative screening method by the American College of Obstetricians and Gynecologist and the Society of Gynecologic Oncology, this screening method has not been universally adopted. Reasons for the lack of universal acceptance of primary high-risk HPV screening over cytology and co-testing are the lack of evidence on comparative effectiveness studies looking at projected lifetime number of screening tests, colposcopies, follow-up visits, direct cost comparisons, and the confusing screening and management algorithms available. 7 
CONCLUSIONS
Expert review of cervical cytology led to diagnosing highergrade lesions from lower-grade lesions and also downgrading some high-and low-grade reports to negative cytology, thereby avoiding invasive procedures with the added cost and patient risk. Universal expert review may not be practical in all settings. In a low-resource setting, expert review could be considered in younger women desiring children to potentially avoid a primary or repeat excisional procedure, which may negatively impact future pregnancies. Consideration could be given to more widespread use of primary HPV testing to eliminate the interobserver differences on Pap test review.
